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Correct function of neuronal networks is enabled by a delicate interplay among neurons
communicating with each other. One of the keys is the communication at chemical
synapses where neurotransmitters like glutamate, GABA, and glycine enable signal
transfer over the synaptic cleft. Thereby, the neurotransmitters are released from the
presynapse and bind as ligands to specific receptors at the postsynaptic side to allow for
modulation of the postsynaptic membrane potentials. The postsynaptic electrical signal,
which is highly modulated by voltage-gated ion channels, spreads over the dendritic
tree and is thus integrated to allow for generation of action potentials at the axon
hillock. This concert of receptors and voltage-gated ion channels depends on correct
function of all its components. Misfunction of receptors and/or voltage-gated potassium
channels (VGKC) leads to diverse adverse effects in patients. Such malfunctions can
be the result of inherited genetic alterations or pharmacological side effects by drugs.
Recently, autoantibodies targeting receptor or channel complexes like NMDAR, AMPAR,
GABA-receptors, glycine receptors, LGI1 or CASPR2 (previously termed as VGKC-
complex antibodies) have been discovered. The presence of specific autoantibodies
against these targets associates with severe forms of antibody-mediated encephalitis.
Understanding the molecular details of autoantibody actions on receptor and VGKC
complexes is highly desirable and may open the path to develop specific therapies to
treat humoral autoimmune encephalitis. Here, we summarize the current knowledge and
discuss technical approaches to fill the gap of knowledge. These techniques include
electrophysiology, biochemical approaches for epitope mapping, and in silico modeling
to simulate molecular interactions between autoantibody and its molecular target.
Keywords: limbic encephalitis, glutamate receptor, ion channel, epitope identification, modeling
The neuronal activity is the basis for normal brain function. Altered activity can result in neuro-
logical diseases like epilepsy, insomnia, hallucinations, schizophrenia, different forms of headache
or autism, and even death (1). Vital for normal brain function is the correct formation of action
potentials in neurons and chemo-electrical communication among neuronal cells. Molecular actu-
ators include voltage-gated potassium channels (VGKC) and ligand-gated ionotropic receptors like
the excitatory glutamate or the inhibitory glycine receptors. Impaired function of these molecular
key players can result from inherited mutations or as side effect of pharmacologically active
compounds. Both, activation and inhibition of molecular targets may lead to disharmonies in the
concert of brain function. Recently, a new entity has been added to the modulators of neuronal
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key players that alter their function: autoantibodies. These
penetrate the blood–brain barrier or are intrathecally synthe-
sized to bind to epitopes of neuronal protein complexes to
alter their function (2). Depending on their glutamate recep-
tor target, these were named as N-methyl--aspartate receptor
(NMDAR) encephalitis (2) or α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) encephalitis (autoan-
tibodies targeting NMDAR or AMPAR) (3). Glutamate receptors
are expressed in various types of benign andmalignant neoplasms,
play a role as growth factors and are important for cancer devel-
opment and progression (4). Expression of glutamate receptors
in tumor cells triggers an anti-tumor immune response, which
can suppress tumor growth and symptoms (5, 6). This tumor
immune response can break the immune tolerance and different
glutamate receptor autoantibodies can attack the neuronal tissue
(paraneoplastic syndrome).
Another form of autoantibody encephalitis is the result of
antibody binding to LGI1 or CASPR2 (7–9). Increasing evi-
dence suggests that interference with LGI1 binding to ADAM22
modulates postsynaptic AMPAR and possibly presynaptic VGKC
(10). These autoantibody encephalitides with plasma membrane
expressed antigens may primarily lead to impaired neurotrans-
mission to cause the specific disease state. The membrane local-
ized autoantibody targets are intracellular proteins involved in
transcription, post-transcriptional RNA regulation, and cytoplas-
mic proteins with various cellular functions. These intracellu-
lar target-associated autoantibody encephalitides are associated
with CD8 T-cell activation and neuronal apoptosis. The clin-
ical manifestations of these pathophysiological events include
forms of limbic encephalitis with epileptic neuronal activity of
the mediotemporal lobe associated with memory impairment,
behavioral aberrations, emotional, and cognitional malfunction.
The latter clinical symptoms are only weakly understood. The
number of cases of neuronal inflammatory autoimmune diseases
is supposedly underestimated.
In recent years, the knowledge about autoantibodies in lim-
bic encephalitis has increased. In this article, we concentrate on
the plasma membrane antigens to understand the pathophys-
iological mechanisms associated with these forms of autoanti-
body encephalitis. Autoantibodies targeting NMDAR have been
reported 8 years ago (2). The autoantibody epitope is located
on GluN1 (1). Retrospective diagnoses have identified a larger
number of cases as autoantibody-NMDAR encephalitis (11).
These findings suggest that anti-NMDAR encephalitis is more
common than previously thought. This knowledge is valuable
as the speed of diagnosis of autoantibody-NMDAR encephali-
tis is key to the success of clinical recovery (1, 12, 13): the
earlier the autoantibody-NMDAR encephalitis is diagnosed and
immunomodulation therapy is started, the better are the chances
for complete recovery of the patient. What is the molecu-
lar–cellular action of autoantibody-NMDAR? First indications
came from application of NMDAR-autoantibodies in hippocam-
pal neurons (14, 15). Zhang et al. and Panaguma et al. showed that
NMDAR-autoantibodies weakened long-term potentiation (LTP)
in hippocampal neurons (15, 16). This shows that LTP in synap-
tic transmission critically depending on NMDAR is substan-
tially weakened. LTP is enabled by intact endocytic cycling via a
RAB5–RAB11 pathway in hippocampal neurons (17). In an elab-
orate study, Hughes et al. showed that NMDAR-autoantibodies
can cluster NMDA-receptors to induce endocytosis (14). Appli-
cation of antibody fragments (FAB) was not effective to induce
endocytosis. When these FABs were clustered by anti-FABs endo-
cytosis was reinduced. The reduction of NMDAR-plasma mem-
brane density was verified in rodent and human hippocampi (14,
18). Using a series of mutant receptor proteins and mass spec-
trometry analyses, Gleichman et al. showed that residue N368 in
GluN1 is glycosylated and modulates electrophysiological effects
of NMDAR-autoantibody binding (19). Binding of NMDAR-
autoantibodies results in prolonged openings of NMDAR leading
to a gain-of-function. However, the reported gain-of-function
by NMDAR-autoantibody binding was later challenged and may
not be indispensable for the reduced NMDAR-plasma membrane
density (18). Post-endocytic trafficking of NMDARs may not be
affected by acute NMDAR-autoantibody binding (18). Interest-
ingly, the region around this glycosylation site controls recogni-
tion by NMDAR-autoantibodies, but glycosylation itself is neither
necessary nor sufficient for NMDAR-autoantibody immunoreac-
tivity (19). Summarizing, NMDAR-autoantibodies bind to their
epitope on the receptor, modulate protein complex conformation
to induce clustering and subsequent endocytosis. However, the
exact physical NMDAR-autoantibody binding site remains to be
proven.
Six years ago, Lai et al. reported on AMPAR-autoantibody
limbic encephalitis (3). Using immunoprecipitation and mass
spectrometry anti-GluA1/GluA2-autoantibodies were identified.
Heterologously expressedGluA1/GluA2 receptors and rodent cul-
tivated hippocampal neurons were used to show immunolocal-
ization and increased anti-GluA1/GluA2-autoantibody-mediated
endocytosis of GluA1/GluA2 complexes (3, 20). ELISA tests
were used to quantify anti-GluA1/GluA2-autoantibodies in can-
cer patients (3). The anti-GluA1/GluA2-autoantibody positive
patients often had tumors and supposedly the anti-GluA1/GluA2-
autoantibodies were directed against these cancers and had sec-
ondary adverse neuronal effects. Unluckily, these patients tended
to suffer from relapse (3). The knowledge about themolecular and
cellular effects of these antibodies has been insufficient.
The current knowledge on the molecular and cellular level of
autoantibody binding to plasma membrane proteins is far from
complete. Several questions remain to be addressed. Hereafter,
we will suggest experimental approaches to stimulate research
regarding pressing questions in this clinically important area.
Why are autoantibodies directed against glutamate receptors,
leucine-rich, glioma inactivated 1 protein, and CASPR2 but not
against Kv1 α-subunits reported?
Membrane protein complexes consist of several protein com-
ponents. Some of them are membrane integral with extracellular
domains of various size and some are intracellular (Figure 1).
Large protein parts of glutamate receptors, LGI1 and CASPR2,
are exposed to the extracellular space. The surfaces of these pro-
tein fractions represent potential epitopes against which (auto-)
antibodies can be directed. On the contrary, a potassium channel
α-subunit extends to the extracellular space with small surfaces
presenting a relatively small area and thus restricted epitopes.
Consistently, (auto-) antibody binding to the large extracellular
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FIGURE 1 | Extracellular surfaces determine the autoantibody
interaction sites. Autoantibodies associated with limbic encephalitis target
different glutamate receptor and Kv channel complexes. Integral proteins with
large extracellular domains present larger surfaces potentially suited as
autoantibody epitopes. Binding of autoantibodies against these proteins with
large extracellular domains is more likely.
FIGURE 2 | Chimeric and homology modeling/docking approach to
identify and simulate autoantibody-target protein interaction.
(A) Construction of a chimera of closely related target proteins but with different
autoantibody binding affinities can help to identify epitope regions in the target
protein. Complementary gain-of-function and loss-of-functional approaches
provide evidence for the location of the interaction region. (B) Models of the
target (GluN1) and the specific IgG can be generated based on solved highly
homologous crystal structural coordinates. Docking of the interaction partner in
the region of the experimentally determined epitope site allows for analysis of
structural effects in silico.
domains of glutamate receptors seems more probable than to Kv1
α-subunit. This oversimplifying hypothesis is based on the idea
that the autoantibodies bind exclusively to extracellularly exposed
protein regions. This hypothesis is supported by the finding that
AMPAR,NMDAR, leucine-rich, glioma inactivated 1 protein, and
CASPR2 but not Kv channel autoantibodies have been reported.
Pathophysiologically relevant autoantibodies against intracellular
epitopes exist as well. These antibodies have to penetrate cellular
membranes to reach their epitopes and are therefore supposedly
less common.
The extracellular epitope idea is helpful to design experi-
mental approaches to identify autoantibody epitopes. For none
of the plasma membrane autoantibody targets, the exact epi-
tope was determined. However, the knowledge of the exact epi-
tope(s) is/are potentially highly valuable to further understand the
autoantibody action. Potentially, the pathophysiological autoan-
tibody–epitope interaction can be disrupted by a synthetic pep-
tide of the epitope, a peptidomimetic or even a small molecule
inhibitor. These compounds could be used to bind to the autoan-
tibodies and outcompete the natural epitopes on the host mem-
brane proteins as a therapeutic option. Such a specific therapy
may be favorable and reduce the undesired side effects intrinsic to
global immunosuppressant therapy. Identification of an autoan-
tibody epitope is technically not trivial. On the other hand, a
series of technical approaches to identify interaction sites between
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proteins or proteins with small molecule modulators exists (21).
A classical approach is to generate chimeras between two closely
related proteins only one of which can bind the ligand. By test-
ing direct binding or testing the functional effect upon binding
and progressively reducing the size of the region of interest, the
putative binding region can be narrowed down. Ideally, gain-of-
function and loss-of-function approaches are adopted in parallel.
When a smaller region is identified, a point mutational approach
in the respective region can identify molecular prerequisites for
the interaction of binding partners. This approach largely leaves
the structural determinants of the interaction site intact, a fact
not accounted for by using fractional peptide-based assays, which
are favorable for misfolded proteins (Figure 2). The design of
(point-) mutants can be aided by structural modeling approaches.
Crystal structures of different glutamate receptors and Kv chan-
nels allow for high-resolution 3D homology modeling. These
models can be used to identify the surface exposed residues. These
residues are potentially involved in the formation of autoanti-
body epitopes. Mutagenesis of only these residues reduces the
experimental effort. Further, the transmembrane and intracellular
regions can be excluded as autoantibody epitopes based on the
extracellular epitope idea (Figures 1 and 2). The interaction of
the autoantibody with its specific target can be assayed by several
approaches. A classical approach would be expression of wt and
mutated membrane protein complexes in Xenopus laevis oocytes
or a cell line like HEK293 cells and functional analyses upon
subsequent autoantibody application. Clearly, a prerequisite of
this approach is that the autoantibody causes clear functional
effects on its target. A disadvantage is that the effect upon binding
but not the binding itself is detected. Alternatively, direct binding
may be detected. Similar to the electrophysiology-based approach,
mutant targets are heterologously expressed. The autoantibody
is applied. Subsequently, the autoantibody is cross-linked by bi-
functional cross-linkers. As a result, the antibody is cross-linked
to the target and can be detected by subsequent target protein
purification and western blotting or mass spectrometry. When
binding of the antibody to the target is disrupted by a specific
mutation the antibody will no longer be cross-linked and co-
precipitated with the target protein. In patient sera, more than one
autoantibody binding different epitopes on the same target can
exist. In this case, the epitopes may cluster in different regions of
the target.
The three dimensional structures of several membrane pro-
teins, including GluN, GluA, and Kv channels, have been solved
(22–24). These high-resolution structures represent very good
templates for homology modeling of the autoantibody targets.
Standard homology modeling will allow for generation and local-
izations of the identified epitopes. If the sequence of the IgG-
autoantibody is known, its structure can be modeled as well.
High-resolution template IgG structures like 1IGT.pdb (25) are
perfectly suited for homology modeling. Molecular docking of
this antibody model to one or two membrane protein targets will
allow to study the molecular details in silico (Figure 2B). If more
than one epitope is targeted by antibodies, the epitopes on the
structural models can show distinct localizations. Dissection of
overlapping epitopes, however, may be difficult. This new struc-
tural knowledge should be useful to develop drug candidates and
therapeutic approaches.
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